Skip to content
AB Science
Masitinib and AB8939 – Two compounds with breakthrough mechanism of action
AB ScienceAB Science
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in neurodegenerative disorders
    • Masitinib in inflammatory diseases
    • Masitinib in oncology
    • Masitinib in viral diseases
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Alzheimer’s Disease
      • Indolent Systemic Mastocytosis
      • Severe Asthma
      • Prostate Cancer
      • Pancreatic Cancer
      • COVID-19
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webconference replay
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting preparation
      • Outstanding shares and voting rights
      • Reports on Regulated Agreements and Commitments
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
    • Events
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact
  • English
  • Français
Search:
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in neurodegenerative disorders
    • Masitinib in inflammatory diseases
    • Masitinib in oncology
    • Masitinib in viral diseases
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Alzheimer’s Disease
      • Indolent Systemic Mastocytosis
      • Severe Asthma
      • Prostate Cancer
      • Pancreatic Cancer
      • COVID-19
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webconference replay
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting preparation
      • Outstanding shares and voting rights
      • Reports on Regulated Agreements and Commitments
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
    • Events
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact

Press releases

You are here:
  1. Home
  2. News and Media
  3. Press releases
  • 2020
  • 2019

Boursorama interview of Alain Moussy, CEO of AB Science

December 23, 2020

23/12/2020 – Read the interview of Alain Moussy, CEO of AB Science, in Boursorama

Read more

Capital raise for a total amount of 15 million euros

December 21, 2020

21/12/2020 – AB Science announces today the success of its capital raise for a total amount of 15 million euros

Read more

Results from phase 2B/3 study evaluating masitinib in Alzheimer’s disease

December 18, 2020

18/12/2020 – AB Science communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer’s disease

Read more

Masitinib in Alzheimer’s Disease Webcast Presentation

December 17, 2020

17/12/2020 – Presentation of the webcast held on December 17, 2020 on masitinib in Alzheimer’s Disease

Read more

Results of the Extraordinary General Shareholders’ Meeting of December 16, 2020

December 17, 2020

17/12/2020 – AB Science provides the results of the Extraordinary Shareholders’ Meeting of December 16, 2020

Read more

Corrective press release regarding adverse events information from study AB09004

December 17, 2020

17/12/2020 – AB Science issues a corrective press release regarding adverse events information from study AB09004 reported on December 16, 2020

Read more

Live webcast on Thursday December 17, 2020 on masitinib’s results in Alzheimer’s Disease

December 16, 2020

16/12/2020 – AB Science will host a live webcast on December 17, 2020 on masitinib results in Alzheimer’s Disease

Read more

Positive Phase 2/3 study AB09004 with masitinib in Alzheimer’s Disease

December 16, 2020

16/12/2020 – AB Science announces that Phase 2B/3 study evaluating masitinib in Alzheimer’s disease met its primary endpoint

Read more

Live webcast on Friday December 11, 2020 on masitinib’s results in pancreatic cancer

December 8, 2020

08/12/2020 – AB Science will host a live webcast on December 11, 2020 with key opinion leaders to discuss recently reported results from the Phase 3 masitinib trial in pancreatic cancer

Read more

Positive confirmatory Phase 3 study AB12005 with masitinib in first line pancreatic cancer with pain

December 4, 2020

04/12/2020 – AB Science announces that confirmatory Phase 3 study AB12005 with masitinib in first line pancreatic cancer with pain met its primary objective to demonstrate increase in survival

Read more

Signature of a 15.0 million financing deal with the European Investment Bank

November 30, 2020

30/11/2020 – AB Science announces the signature of a 15.0 million financing deal with the European Investment Bank to support clinical development of masitinib in Covid-19

Read more

Equity financing for a maximum of 4 million shares with Alpha Blue Ocean’s PACT

November 16, 2020

16/11/2020 – AB Science secures equity financing for a maximum of 4 million shares with Alpha Blue Ocean’s PACT

Read more

Financing of 4.5 million euros through the issuance of bonds convertible into new ordinary shares

October 29, 2020

29/10/2020 – AB Science announces a financing of 4.5 million euros through the issuance of bonds convertible into new ordinary shares

Read more

Positive top-line Phase 3 results for oral masitinib in severe asthma

October 20, 2020

20/10/2020 – AB Science announces positive top-line Phase 3 results for oral masitinib in severe asthma

Read more

Results from masitinib study AB07015 in severe asthma selected for presentation at an American Thoracic Society symposium

October 13, 2020

13/10/2020 – Results from masitinib study AB07015 in severe asthma selected for presentation at an American Thoracic Society (ATS) symposium held on October 16, 2020

Read more

First half of 2020 results

September 30, 2020

30/09/2020 – AB Science reports its revenues for the first half of 2020

Read more

AB Science Presents Phase 2B/3 Study Results in Progressive Multiple Sclerosis at the World’s Largest Multiple Sclerosis Research Conference

September 14, 2020

14/09/2020 – AB Science presents Phase 2B/3 study results in Progressive Multiple Sclerosis at the world’s largest Multiple Sclerosis research conference

Read more

AB Science to present results from its AB07015 study in severe asthma at the annual European Respiratory Society International Congress

September 8, 2020

08/09/2020 – AB Science to present results from its Phase 3 AB07015 study in severe asthma at the annual European Respiratory Society International Congres

Read more

AB Science to present results from its AB07002 study in progressive forms of MS at MSVirtual2020

September 7, 2020

07/09/2020 – AB Science to present results from its Phase 2B/3 AB07002 study in progressive forms of multiple sclerosis at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting

Read more

New independent research reveals that masitinib has direct anti-viral activity against the SARS-CoV-2 virus in vitro

September 2, 2020

02/09/2020 – New independent research reveals that masitinib has direct anti-viral activity against the SARS-CoV-2 virus in-vitro and is a promising candidate for treating COVID-19  

Read more

Results of the Combined General Shareholders’ Meeting of August 31, 2020

September 1, 2020

01/09/2020 – AB Science announces the results of the Combined Shareholders’ Meeting of August 31, 2020

Read more

New results published in Journal of Alzheimer’s Disease support masitinib’s potential mode of action in Alzheimer’s Disease

July 8, 2020

08/07/2020 – AB Science announces that new results published in the peer-reviewed Journal of Alzheimer’s Disease support masitinib’s potential mode of action in Alzheimer’s Disease

Read more

Presentation of the results from AB8939 preclinical program in AML in EHA 2020 Annual Congress

June 10, 2020

10/06/2020 – AB Science will present results from AB8939 preclinical program in acute myeloid leukemia at the EHA 2020 Annual Congress

Read more

Postponement of AB Science Annual General Shareholders’ meeting

May 22, 2020

22/05/2020 – AB Science announces the postponement of its annual general shareholders’ meeting

Read more

Live webcast on masitinib in combination with isoquercetine for the treatment of COVID-19 on Monday May 11, 2020

May 7, 2020

07/05/2020 – AB Science will host a live webcast on masitinib in combination with isoquercetin for the treatment of COVID-19 on Monday May 11, 2020  

Read more

Presentation of the results from the Phase 3 AB07015 study in severe asthma at the EAACI 2020 Annual Congress

May 7, 2020

07/05/2020 – AB Science will present results from its Phase 3 study in severe asthma at the EEACI 2020 Annual Congress

Read more

Authorization by ANSM to initiate Phase 2 study evaluating masitinib in combination with isoquercetin for the treatment of COVID-19

May 6, 2020

06/05/2020 – AB Science granted authorization by ANSM to initiate Phase 2 study evaluating masitinib in combination with isoquercetin for the treatment of COVID-19

Read more

Annual financial results as of 31 December, 2019

April 30, 2020

30/04/2020 – AB Science reports its annual financial results as of 31 December, 2019

Read more

Letter to our stakeholders on COVID-19 pandemic impact on AB Science studies

April 3, 2020

03/04/2020 – A letter to our stakeholders on COVID-19 pandemic impact on AB Science clinical studies

Read more

Summary of webcast with Key Opinion Leaders on masitinib Phase 2B/3 results in Progressive Forms of MS

March 9, 2020

09/03/2020 – AB Science provides a summary of the live webcast held on March 6 2020 with key opinion leaders on progressive froms of multiple sclerosis

Read more

New fundraising of EUR 12.3 million

March 1, 2020

02/03/2020 – AB Science announces a new fundraising of EUR 12.3 million

Read more

Positive top-line Phase 2B/3 results for masitinib in progressive forms of MS

February 20, 2020

20/02/2020 – AB Science announces positive top-line Phase 2B/3 results for oral masitinib in progressive forms of multiple sclerosis

Read more

FDA green-lights U.S. patient enrollment in masitinib phase 3 study in metastatic castrate-resistant prostate cancer

January 8, 2020

08/01/2020 – FDA green-lights U.S. patient enrollment in masitinib phase 3 study following IND clearance in metastatic castrate-resistant prostate cancer eligible to chemotherapy

Read more

Publication of new results in in the peer-reviewed journal Glia that further support masitinib’s potential mode of action in ALS

December 23, 2019

23/12/2019 – AB Science announces publication of new results in the peer-reviewed journal Glia that further support masitinib’s potential mode of action in ALS

Read more

Publication of three AB8939 scientific abstracts in the special ASH Annual Meeting issue of Blood

December 9, 2019

09/12/2019 – AB Science announces publication of three AB8939 scientific abstracts in the special ASH Annual Meeting issue of Blood

Read more

Webcast on masitinib in severe asthma on Monday, December 2, 2019

November 26, 2019

27/11/2019 – AB Science will host a live webcast on masitinib in severe asthma on Monday December 2, 2019

Read more

Summary of webcast with Key Opinion Leaders on Indolent Systemic Mastocytosis

November 25, 2019

25/11/2019 – AB Science provides a summary of the live webcast on November 20 with key opinion leaders on Indolent Systemic Mastocytosis (ISM)

Read more

Clarification regarding the article in the newspaper Les Echos related to the investigation by the French market authorities

November 22, 2019

22/11/2019 – AB Science provides clarification regarding the article in the newspaper Les Echos related to the investigation by the French market authorities

Read more

Positive top-line Phase 3 results for masitinib in severe asthma

November 7, 2019

07/11/2019 – AB Science announces positive top-line phase 3 results for oral masitinib in severe asthma

Read more

AB8939 receives Orphan Drug Designation for Acute Myeloid Leukemia from FDA

November 7, 2019

07/11/2019 – AB Science announces that AB8939 receives Orphan Drug Designation for Acute Myeloid Leukemia from FDA

Read more

First presentation of preclinical results for compound AB8939 in the 61st ASH Annual Meeting

November 6, 2019

06/11/2019 – AB Science announces the first presentation of preclinical results of compound AB8939 in the 61st ASH Annual meeting online program

Read more

Financing agreement to pre-finance the 2019 research tax credit

November 6, 2019

06/11/2019 – AB Science has signed a financing agreement in order to pre-finance the 2019 research tax credit

Read more

Webcast on indolent systemic mastocytosis on November 20, 2019

November 4, 2019

04/11/2019 – AB Science will host a live webcast on indolent systemic mastocytosis on November 20,2019

Read more

Authorization to initiate phase 3 confirmatory study in mastocytosis

October 24, 2019

24/10/2019 – AB Science granted authorization to initiate phase 3 confirmatory study of masitinib in indolent systemic mastocytosis

Read more

Update on masitinib programs timelines

October 10, 2019

10/10/2019 – AB Science provides update on masitinib programs timelines

Read more

First half of 2019 results

September 30, 2019

30/09/2019 – AB Science reports its revenues for the first half of 2019

Read more

10M€ raised through a private placement

August 19, 2019

19/08/2019 – AB Science announces the success of a private placement

Read more

AB Science to present at two upcoming conferences in September 2019

August 12, 2019

12/08/2019 – AB science will present a corporate overview at two upcoming healthcare conferences in September 2019, in New York.

Read more

Update on masitinib clinical program

August 5, 2019

05/08/2019 – AB Science provides an update on its masitinib clinical program.

Read more

Results of masitinib study in metastatic melanoma

August 2, 2019

02/08/2019 – AB Science reports the analysis for its phase 3 trial evaluating masitinib in patients with non-resectable or metastatic stage 3 or stage 4 melanoma.

Read more

AB Science Corporate Presentation

July 22, 2019

22/07/2019 – AB Science Corporate Presentation – July 2019  

Read more

Summary of the webconference held on July 8, 2019

July 9, 2019

09/07/2019 – AB Science is providing a summary of the web conference held on July 8, 2019

Read more

July 8 2019 web conference presentation

July 8, 2019

08/07/2019 – AB Science web conference presentation

Read more

Publication of the positive phase 2/3 clinical trial with masitinib in ALS in the journal ALSFD

July 8, 2019

08/07/2019 – AB Science announces the publication of the positive phase 2/3 clinical trial with masitinib in ALS in the journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration.

Read more

Validation of the AB8939 clinical development plan through regulatory authority Scientific Advice procedure

July 4, 2019

04/07/2019 – AB Science announces the European Medicine Agency has validated the clinical development program for its new compound AB8939 in acute myeloid leukemia (AML) through a Scientific Advice procedure.

Read more

Results of interim analysis for masitinib in Alzheimer’s Disease

June 26, 2019

26/06/2019 – AB Science reports the outcome from the interim analysis of study AB09004 in Alzheimer’s Disease

Read more

June 14 2019 web conference presentation

June 14, 2019

14/06/2019 – AB Science web conference presentation

Read more

Positive IDMC recommendation following interim analysis in pancreatic cancer

June 12, 2019

12/06/2019 – AB Science announces the positive recommendation of IDMC following the interim analysis of AB12005 study in the first-line treatment of pancreatic cancer

Read more

Upcoming news flow

June 10, 2019

10/06/2019 – AB Science is providing the upcoming news flow of the Company

Read more

Updated corporate overview

June 10, 2019

10/06/2019 – AB Science is providing an updated coporate overview of the Company

Read more

Summary of the webconference held on June 5, 2019

June 5, 2019

05/06/2019 – AB Science is providing a summary of the web conference held on 5 June, 2019

Read more

June 5 2019 web conference presentation

June 5, 2019

05/06/2019 – AB Science web conference – Part 2

Read more

Summary of the webconference held on June 4, 2019

June 4, 2019

04/06/2019 – AB Science is providing a summary of the web conference held on 4 June, 2019

Read more

June 4 2019 web conference presentation

June 4, 2019

04/06/2019 – AB Science web conference presentation (Part 1)

Read more

Web conference on June 4 and 5, 2019

May 30, 2019

30/05/2019 – AB Science will hold a web conference on its outlook for 2019 on June 4 and 5, 2019 from 5.30 pm to 7pm CET

Read more

Lifting of the ANSM clinical hold

May 28, 2019

28/05/2019 – AB Science announces the lifting of the ANSM clinical hold.

Read more

Annual financial results as of 31 December, 2018

April 30, 2019

30/04/2019 – AB Science reports its annual financial results as of 31 December 2018.

Read more

Presentation of new masitinib preclinical data in ALS at the 2019 Muscular Dystrophy Association Conference

April 16, 2019

16/04/2019- AB Science presented new preclinical data for masitinib in ALS at the 2019 Muscular Dystrophy Association Conference.

Read more

Acceptance of abstract for oral presentation at the 2019 Muscular Dystrophy Association Conference

March 21, 2019

21/03/2019 – AB Science announces acceptance of abstract for oral presentation at the 2019 Muscular Dystrophy Association Conference.

Read more
Previous tab Next tab

AB SCIENCE HEADQUARTER

3, Avenue George V – 75008 PARIS – FRANCE
Tel. : +33 (0)1 47 20 00 14
Fax. : +33 (0)1 47 20 24 11

GENERAL INQUIRIES

contact@ab-science.com

PRODUCT INQUIRIES

masivet@ab-science.com

JOB INQUIRIES

careers@ab-science.com

CLINICAL INQUIRIES

clinical@ab-science.com

MEDIA / FINANCIAL INQUIRIES

investors@ab-science.com

PHARMACOVIGILANCE

pharmacovigilance@ab-science.com
Fax : +33 1 47 20 10 82

AB Science
© AB Science – All right reserved
Go to Top